About Us
About Us
Our Science
Commercial Opportunities
Investors
Latest News
Bone Marrow Transplantation (2023)
Technical Reports:
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy
Mission
GreenJay Therapeutics, Inc. (GreenJay) is a clinical-stage pharmaceutical
company based in Conroe (Houston), Texas, focused on reformulation of drugs
with significant deficiencies. The Company has developed a new formulation
of IV busulfan as a pretreatment related to stem cell transplantation. Current
IV formulations of busulfan on the market contain a toxic excipient whereas
the new formulation developed by GreenJay does not. This new formulation of IV Busulfan, Bulanta™, may
be approved by the FDA without the requirement for additional clinical trials.